BACKGROUND: We evaluated the association of symptoms of anxiety and depression with fatal and non-fatal cardiovascular disease events among patients with coronary heart disease and considered several potential underlying pathogenetic links. DESIGN: This was a prospective cohort study. METHODS: In this study, including coronary heart disease patients undergoing an in-patient rehabilitation program, symptoms of anxiety and depression were evaluated with the Hospital Anxiety and Depression Scale (HADS). Fatal and non-fatal cardiovascular disease events were determined during a 3-year follow-up. RESULTS: Of the 1052 patients with CHD 16.1% showed a borderline and 8.3% a manifest anxiety symptoms score, whereas 11.8 and 5.9% showed a borderline and manifest depressive symptoms score, respectively. During the 3-year follow-up fatal and non-fatal cardiovascular disease events were observed in 73 (6.9%) patients. After adjustment for covariates, patients having manifest anxiety symptoms had a statistically significant hazard ratio (HR) of 2.32 [95% confidence interval (CI) 1.14-4.74] for a cardiovascular disease event, and patients with depressive symptoms had an HR of 1.47 (95% CI 0.62-3.51) compared to other patients. In a model considering anxiety and depressive symptom scores simultaneously, the hazard ratio for a cardiovascular disease event associated with anxiety symptoms increased to 3.31 (95% CI 1.32-8.27), whereas the hazard ratio associated with depressive symptoms decreased (HR 0.62; 95% CI 0.20-1.87). We found a positive association of increased anxiety scores with body mass index and systolic blood pressure. CONCLUSIONS: The study suggests an important role especially for symptoms of anxiety for long-term prognosis of patients with known coronary heart disease. It furthermore suggests that several pathogenetic links may partly explain the increased risk.
BACKGROUND: We evaluated the association of symptoms of anxiety and depression with fatal and non-fatal cardiovascular disease events among patients with coronary heart disease and considered several potential underlying pathogenetic links. DESIGN: This was a prospective cohort study. METHODS: In this study, including coronary heart diseasepatients undergoing an in-patient rehabilitation program, symptoms of anxiety and depression were evaluated with the Hospital Anxiety and Depression Scale (HADS). Fatal and non-fatal cardiovascular disease events were determined during a 3-year follow-up. RESULTS: Of the 1052 patients with CHD 16.1% showed a borderline and 8.3% a manifest anxiety symptoms score, whereas 11.8 and 5.9% showed a borderline and manifest depressive symptoms score, respectively. During the 3-year follow-up fatal and non-fatal cardiovascular disease events were observed in 73 (6.9%) patients. After adjustment for covariates, patients having manifest anxiety symptoms had a statistically significant hazard ratio (HR) of 2.32 [95% confidence interval (CI) 1.14-4.74] for a cardiovascular disease event, and patients with depressive symptoms had an HR of 1.47 (95% CI 0.62-3.51) compared to other patients. In a model considering anxiety and depressive symptom scores simultaneously, the hazard ratio for a cardiovascular disease event associated with anxiety symptoms increased to 3.31 (95% CI 1.32-8.27), whereas the hazard ratio associated with depressive symptoms decreased (HR 0.62; 95% CI 0.20-1.87). We found a positive association of increased anxiety scores with body mass index and systolic blood pressure. CONCLUSIONS: The study suggests an important role especially for symptoms of anxiety for long-term prognosis of patients with known coronary heart disease. It furthermore suggests that several pathogenetic links may partly explain the increased risk.
Authors: Judson B Williams; Karen P Alexander; Jean-François Morin; Yves Langlois; Nicolas Noiseux; Louis P Perrault; Kim Smolderen; Suzanne V Arnold; Mark J Eisenberg; Louise Pilote; Johanne Monette; Howard Bergman; Peter K Smith; Jonathan Afilalo Journal: Am J Cardiol Date: 2013-01-01 Impact factor: 2.778
Authors: Thomas Rutledge; Sarah E Linke; David S Krantz; B Delia Johnson; Vera Bittner; Jo-Ann Eastwood; Wafia Eteiba; Carl J Pepine; Viola Vaccarino; Jennifer Francis; Diane A Vido; C Noel Bairey Merz Journal: Psychosom Med Date: 2009-10-15 Impact factor: 4.312
Authors: M Urooj Zafar; Manuel Paz-Yepes; Daichi Shimbo; Gemma Vilahur; Matthew M Burg; William Chaplin; Valentin Fuster; Karina W Davidson; Juan J Badimon Journal: Eur Heart J Date: 2010-01-22 Impact factor: 29.983